Nanomedicines are redefining pharmaceutical innovation, but their complexity demands advanced analytical solutions.
In this whitepaper, Ardena explores the analytical and regulatory challenges of characterizing nanoparticle-based drug delivery systems, and how state-of-the-art techniques like AF4-MALS-DLS can provide critical insights into particle size, morphology, stability, and drug loading.
Gain a deeper understanding of:
– How to identify and validate Critical Quality Attributes (CQAs)
– The limitations of conventional techniques like DLS
– Regulatory trends and the path toward standardization
Read the full whitepaper.
Thank you for your interest in our scientific content.
